Large-scale testing (Phase 3)Study completedNCT04209205
What this trial is testing
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Who this might be right for
Psoriatic Arthritis
Novartis Pharmaceuticals 381